Big pharma plans Phase 2 Alzheimer’s trial of Vigil’s oral TREM2 agonist designed to convert microglia into their neuroprotective state.
Pharma giant Sanofi has completed its acquisition of Vigil Neuroscience, aiming to bolster its early-stage neurology portfolio with assets focused on neurodegenerative diseases. The deal will see Vigil’s lead drug candidate, VG-3927, an oral small-molecule TREM2 agonist, enter into a Phase 2 trial for Alzheimer’s disease and folds the biotech’s research capabilities into Sanofi’s broader effort to apply immunology to central nervous-system disorders.
VG-3927 is designed to modulate microglial function, a therapeutic approach predicated on the idea that restoring or enhancing microglial activity could reduce debris accumulation, tamp down chronic inflammation and slow neurodegeneration. Activation of TREM2 emphasize effects on microglial migration to damaged areas, as well as enhancing their capacity for phagocytosis, proliferation and survival – cellular functions that could be protective in adult-onset neurodegenerative conditions. Sanofi plans to move VG-3927 into a phase 2 study in patients with Alzheimer’s disease.
“TREM2 represents a compelling target at the intersection of immune dysregulation and neurodegeneration, particularly in people living with Alzheimer’s because they face devastating cognitive decline with limited treatment options,” said Sanofi’s head of R&D, Dr Houman Ashrafian. “Vigil’s expertise is complementary to our capabilities in neurology and reinforces our dedication to developing innovative medicines to improve people’s lives.”
The deal reflects Sanofi’s broader R&D strategy, which pairs targeted equity investments with acquisitions to increase optionality in addressing unmet medical needs. Folding Vigil’s team and preclinical assets into Sanofi’s portfolio is intended both to accelerate VG-3927’s clinical development and to expand the company’s research reach across other neurodegenerative indications.
“We look forward to joining forces with Sanofi’s team to leverage Sanofi’s resources, broad platform and far-reaching network to fully unlock and accelerate the development of VG-3927 for the potential treatment of Alzheimer’s disease – a devastating disease with significant unmet need,” said Vigil CEO Dr Ivana Magovčević-Liebisch.
Sanofi, which counts neurology among four strategic disease areas, had already signaled its interest in Vigil with a strategic $40 million investment in June 2024 that included an exclusive right of first negotiation for rights to VG-3927. The acquisition transfers all outstanding common shares of Vigil to Sanofi for $8 a share in cash at closing, valuing the company at roughly $470 million on a fully diluted basis. In addition, Vigil shareholders received a non-transferable contingent value right that will pay $2 per share if and when VG-3927 achieves a first commercial sale. The transaction excludes VGL101, Vigil’s second clinical program, which was not acquired.
